Kelso Pharma, the growing UK based specialty pharmaceuticals business, has appointed experienced pharma executive, Giovanni Mauri, as General Manager at Velit Biopharma, the Italian-based pharma business that was acquired by Kelso Pharma in November 2023.
With a wealth of experience across a variety of key markets in the life sciences sector, Giovanni Mauri specialises in strategic business development and licensing operations and brings with him significant experience in legal and compliance. Previous roles include Business Development Manager at Bausch + Lomb, the largest global provider of eye care products, and Chief Business Development Officer at NTC Pharma, an international R&D-driven pharmaceuticals company. Dr Nicola Travierso, founder of Velit Biopharma, will act as a senior advisor to Mr Mauri.
Velit Biopharma specialises in developing and registering “hard to make” medicines and medical devices which it then makes available to patients through partnerships with pharmaceutical companies and distributors across Europe, Asia, Middle East and Africa. It has more than 100 partnerships in 48 regions/countries covering 167 products.
Kelso Pharma is focused on bringing innovative, value added, specialty medicines to international healthcare markets, providing medicines that improve the lives of patients in a cost-effective and ethical manner. The company is growing through a blend of company and product acquisitions, partnerships and organic growth internationally.
The appointment of Mr Mauri continues a strong period of growth across the Kelso Pharma Group, with Stirling Anglian Pharmaceuticals, Velit Biopharma and the recently acquired ALTURiX, enhancing the business across its product and partnership capabilities.
Commenting on the appointment, Kelso Pharma CEO, Dr. Tom Stratford, said:
“We’re pleased to welcome Giovanni to Kelso Pharma, playing a vital role in the continued growth and expansion of our European operations as General Manager at Velit Biopharma.
“At Kelso Pharma, we have ambitious goals to bring in more products and continue to build our infrastructure across the UK and Europe and Giovanni joining the Kelso Pharma Group is a very important step in the future of our business.”
Giovanni Mauri, added:
“I’m thrilled to be joining Velit Biopharma and becoming part of Kelso Pharma in this exciting phase of growth for the business. I’m looking forward to working with my new colleagues and helping drive our business forward across Europe as we continue to identify products and partners which will help us to scale in the coming years.”
